Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
The AACR Annual Meeting 2026 concluded April 22 in San Diego after six days featuring unprecedented peptide-oncology visibility. Macrocyclic peptide drug conjugate (PDC) pipelines across Circle Pharma, Bicycle Therapeutics, Oncopeptides, and SignaBlok drew regulatory and venture attention; peptide-targeting radioligand data from Perspective Therapeutics, Bicycle, and AlphaGen signaled maturation of the peptide-radioconjugate subcategory. AACR Advances sessions throughout the meeting featured targeted protein degradation and novel tumor-selective modalities, with peptide-based approaches competing directly with antibody drug conjugates in Phase 1/2 readouts.
Swiss peptide CDMO Bachem announced a strategic partnership and asset acquisition in April 2026 to scale large-scale peptide API production. The move responds to surging demand for GLP-1 and next-generation peptide drugs — the global peptide synthesis market is now projected to reach $2.26 billion by 2033 at an 11.4% CAGR. Bachem previously secured a CHF 1 billion peptide supply contract and is operating three site expansions to address capacity constraints that have periodically disrupted semaglutide and tirzepatide supply.
Eli Lilly shares closed down nearly 2% at $918.56 and Novo Nordisk fell ~4% on April 22 after CVS Health's decision to opt out of the Medicare obesity drug coverage pilot triggered CMS to scrap the BALANCE model. The combined market cap loss across the two GLP-1 leaders exceeded $25 billion. Hims & Hers dropped another 6% on continued Amazon One Medical competitive pressure.
Telehealth rival Hims & Hers Health shares slid 6% April 21-22 after Amazon's One Medical launched a comprehensive GLP-1 weight management program offering Wegovy and Foundayo starting at $25/month with insurance or $149/month cash-pay for oral options. The move positions Amazon against established telehealth obesity care providers (Hims, Ro, LifeMD, Noom) as the compounded-GLP-1 era winds down.
Amazon One Medical launched a nationwide GLP-1 Management Program offering Wegovy, Zepbound, and Lilly's Foundayo starting at $25/month with insurance, plus $149/month cash-pay for oral drugs and $299/month for injectables. Same-day delivery in nearly 3,000 cities, expanding to 4,500 by year-end. Shares of Eli Lilly, Novo Nordisk, and Hims & Hers fell on the news.
Obesity biotech Kailera Therapeutics priced an upsized IPO of 39.06 million shares at $16, raising $625 million — the largest venture-backed biopharmaceutical IPO since Acelyrin in 2023. Lead candidate ribupatide (a GLP-1/GIP peptide dual agonist) drove 18% body weight loss at 48 weeks in a late-stage Chinese study; global Phase 3 readout expected in 2028.
A new market landscape report published April 21 projects the global peptide drug conjugate market will exceed $1.5 billion by 2031, with >14% CAGR and coverage of more than 50 peptide conjugates currently in clinical development. Commercial PDC benchmarks include Novartis's Lutathera and Pluvicto and Bicycle Therapeutics' nuzefatide pevedotin, with earlier-stage pipelines from Zymeworks, Bicycle, PeptiDream, and others.
A DelveInsight market analysis published April 20 projects 7.3% CAGR growth in the pheochromocytoma and paraganglioma treatment market through 2036, driven by SSTR2 analogs and peptide receptor radionuclide therapies including Novartis's Lutathera (lutetium-177 dotatate). PRRT remains one of the few FDA-approved peptide therapeutics for rare neuroendocrine tumors, binding SSTR2 to deliver targeted radiation.
The AACR 2026 Opening Plenary Session — 'Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally' — runs Sunday April 19, 9:30-11:30 a.m. PT. Cochaired by Paul Mischel (Stanford) and Alice Shaw (Dana-Farber), speakers include Carl June (Penn, armored CAR-T for solid tumors, glioblastoma), Georg Winter (AITHYRA), Regina Barzilay (MIT), and Charles Sawyers (MSK). The program sets the tone for a meeting in which peptide-based modalities, ADCs, and PDCs are taking center stage.
Verismo Therapeutics announced a $28 million investment from HLB Innovation to accelerate clinical development of its KIR-CAR platform, timed to the company's first-ever presentation of SynKIR-110 Phase 1 (STAR-101) multi-chain KIR-CAR clinical data in the AACR 2026 Late-Breaking Clinical Trials plenary (April 20). Verismo is a Penn/Carl June spinout using a modified NK-cell-derived receptor and DAP12 pairing to improve T-cell persistence.
PharmaTher Holdings filed a U.S. provisional patent on April 13 for stabilized peptide compositions delivered via its PharmaPatch microneedle platform, covering formulations for BPC-157, GHK-Cu, TB-500, KPV, and multi-peptide combinations. The April 16 announcement positions PharmaTher to capture needle-free delivery share if the FDA's July PCAC meeting moves peptides back to Category 1. Three of the four compounds are on the July agenda.
The European Society of Clinical Microbiology & Infectious Diseases (ESCMID) Global 2026 opened today at Messe München, running April 17-21 with ~18,000 international participants. Antimicrobial resistance dominates the agenda, with presentations featuring novel antimicrobial peptides, peptide-antibody hybrids, and AI-driven AMP discovery platforms. ESCMID is the largest international clinical microbiology and infectious diseases conference worldwide.
ApexOnco analysis frames AACR 2026 as a breakout moment for private peptide-based biotechs. Circle Pharma (macrocyclic peptides), Bicycle Therapeutics (bicyclic peptide drug conjugates), and SignaBlok (TREM-1 peptide) all landed prominent slots. Antibody-drug and peptide-drug conjugates remain the dominant theme, with conjugate-related abstracts outpacing any other modality in the clinical late-breaker sessions.
CNBC analysis frames Hims & Hers Health as the biggest direct-to-consumer beneficiary of the FDA's July PCAC meeting. Hims acquired a California peptide manufacturing facility in 2025 and can convert its GLP-1 compounding infrastructure to peptide production. The stock closed up 11.07% on April 16 after the FDA announcement; Bank of America raised its price target from $21 to $25, citing the platform's conversion potential.
The American Association for Cancer Research (AACR) Annual Meeting 2026 opens April 17 at the San Diego Convention Center, running through April 22 with 9,500+ sessions, 575 clinical abstracts, 56 clinical trial plenary talks, and 393 late-breaking posters. Multiple peptide biotechs — including Bicycle Therapeutics, Circle Pharma, SignaBlok, and Oncolytics Biotech — are presenting new clinical and preclinical data on macrocyclic peptides, bicyclic peptide drug conjugates, and peptide-based immunotherapies.
Novo Nordisk and OpenAI announced a partnership to deploy AI across R&D, manufacturing, and corporate functions, with pilot programs launching immediately and full integration targeted by end of 2026. The deal positions Novo to analyze complex datasets, identify new drug candidates, and compress R&D timelines as it fights to claw back market share from Eli Lilly. OpenAI will also provide AI literacy training to Novo's global workforce.
Motley Fool analysis argues that retatrutide — Lilly's triple GLP-1/GIP/glucagon agonist showing up to 28.7% weight loss in Phase 3 TRIUMPH-4 — is the one thing that could firmly cement Lilly's dominance in the obesity drug market. With seven additional Phase 3 readouts expected in 2026 and a projected 2028 launch, retatrutide positions Lilly to extend its lead over Novo Nordisk.
Fifty 1 Labs (OTC:FITY) announced the expansion of its peptide discovery and clinical research strategy targeting musculoskeletal health, recovery, and performance. The company is building a proprietary peptide discovery engine focused on MSK biology, combining AI-enabled design with staged clinical development for muscle, tendon, ligament, and bone conditions — an area largely overlooked by the GLP-1 dominated peptide pipeline.